NSE: SYNGENE | BSE: 539268

Slowing Down Stock

Download real time

635.50 3.90 (0.62%)

33.84% Fall from 52W High

523.3K NSE+BSE Volume

NSE 03 Oct, 2025 3:31 PM (IST)

25,606.8

Market Cap

High in industry

0.9

Beta 1Year

Low volatility

Syngene International Ltd. share price target and research reports

Latest analyst research reports with target prices and PDF download for SYNGENE, BSE:539268 Syngene International Ltd.

Syngene International Ltd.

31 Jul 2017

635.50

0.62%

Result Updates

Buy: Syngene International Ltd.

Target

Angel Broking

Syngene's net sales grew by 6% yoy to Rs 291cr and PAT grew by 3.7% yoy to Rs 62cr. EBITDA grew by 8.1% to Rs 96cr due to margin improvement led by superior business mix. EBITDA margin improved to 33% in 1QFY18 from 32.3% in 1QFY17.. We had expected PAT of Rs 61cr on the topline of Rs 296cr hence the result has met our expectations. What ..

Syngene International Ltd. is trading below all available SMAs

Syngene International Ltd.

31 Jul 2017

635.50

0.62%

Syngene International Ltd

Hold: Syngene International Ltd.

ICICI Securities Limited

SIL's revenues grew at ~24% CAGR in FY12-17 to | 1201 crore due to new client addition on a regular basis and scaled up revenues from existing clients led by integrated service offerings, high data integrity ethos and continuous endeavour to move up the value chain. The capabilities have been vindicated by proven customer stickiness as eight of the top 10 global pharma companies have been availing the services for the last five years. The proposed foray in contract manufacturing (CMO) services will further strengthen its service offering to clients. The...

Syngene International Ltd. has lost -30.11% in the last 1 Year

Syngene International Ltd.

06 Jul 2017

635.50

0.62%

Initiating Coverage

Buy: Syngene International Ltd.

Angel Broking

Unique investment opportunity in drug research business: While almost all Indian pharma companies are in generic drugs business, Syngene supports its clients to invent new drugs. It has 8 of the top 10 global pharma companies as its clients and also has long term contracts with some big pharma companies. In our view Syngene provides a uni..

Syngene International Ltd. is trading below all available SMAs

Syngene International Ltd.

20 May 2017

635.50

0.62%

Syngene International Ltd Q4FY17 results comment

Results Update: Syngene International Ltd.

HDFC Securities

Revenue decreased by 12.29% to Rs. 291.3 Cr in Q4FY17 when compared to the previous quarter. Also it fell by 12.13% when compared with Q4FY16.

Syngene Internationa.. has an average target of 1030.00 from 1 broker.

Syngene International Ltd.

04 May 2017, 12:00AM

635.50

0.62%

Result Update:Syngene Intl.

Hold: Syngene International Ltd.

Axis Direct

We cut FY18/19 EPS by 6% /4% to factor in fire incident and higher costs guidance (impacting margin by 2-3%), but maintain HOLD with a revised TP of Rs 500 at 24x FY19E EPS (vsRs. 520 earlier).

Syngene International Ltd. has lost -30.11% in the last 1 Year

Syngene International Ltd.

02 May 2017

635.50

0.62%

Syngene International Ltd

Hold: Syngene International Ltd.

ICICI Securities Limited

Global pharmaceutical players are facing structural issues from the impending patent cliff, shrinking product pipeline, rising R&D; costs and growing competition. At the one end, these companies are shrinking in size due to loss of blockbuster exclusivities while, at the other end, new product approvals by the USFDA are also on the rise. Hence, to maintain the structural balance and improve probability of success they are inclined to outsource a substantial part of the R&D; work. Similarly, the innovative/virtual companies that are extensively working on new...

Syngene International Ltd. is trading below all available SMAs

Syngene International Ltd.

02 Feb 2017

635.50

0.62%

Result Update:Syngene Intl.

Hold: Syngene International Ltd.

Axis Direct

Syngene's (SYNG) Q3FY17 revenue (up 18% YoY) was in line with estimates, aided by sales return.EBITDA margin was inline at 34%, impacted by higher staff costs on account of senior hiring. We believe the recent fire at a facility in Dec'16 could affect capacity for future growth (as it would take..

Syngene International Ltd. is trading below all available SMAs

Syngene International Ltd.

27 Jan 2017

635.50

0.62%

Syngene International Ltd

Hold: Syngene International Ltd.

ICICI Securities Limited

...

Number of FII/FPI investors decreased from 332 to 279 in Jun 2025 qtr

Syngene International Ltd.

24 Oct 2016

635.50

0.62%

Syngene International Ltd

Hold: Syngene International Ltd.

ICICI Securities Limited

ICICI Securities Ltd | Retail Equity Research Revenues grew 15.9% YoY to | 303 crore (I-direct estimate: | 326 crore) mainly due to strong growth in dedicated centres and discovery services, which was partially offset by slow down in Development and Manufacturing services EBITDA margins increased 376 bps to 34.9% YoY (I-direct estimate:...

Syngene International Ltd. has lost -30.11% in the last 1 Year

Is Syngene International Ltd. worth buying?

243 Votes:

Buy 75.72%

Sell 14.4%

Hold 9.88%

RESEARCH REPORTS

Buy SEE REPORTS >

pdf

Buy SEE REPORTS >

pdf